Dose age affect the efficacy of molecular targeted agents in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis
Metrics: PDF 647 views | HTML 1023 views | ?
Jing Du1,2, Ye Mao1,2, Ming Liu3, Yan Tie1,2, Hai Huang4, Jian Zhao4, Zhongzheng Xiang4 and Di Luo4
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China
2Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
3Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China
4West China Medical School, West China Hospital, Sichuan University, Chengdu, China
Jing Du, email: email@example.com
Ming Liu, email: firstname.lastname@example.org
Keywords: hepatocellular carcinoma, elderly, randomized controlled trials, meta-analysis
Received: August 14, 2017 Accepted: September 20, 2017 Published: October 19, 2017
Currently, whether the impact of age on efficacy of molecular targeted agents (MTAs) in the treatment of hepatocellular carcinoma (HCC) patients remains undetermined. We searched databases and abstracts presented at ASCO meeting to identify relevant studies. The endpoints were overall survival (OS) and progression-free survival (PFS). Data were examined using age cutoffs of 65 years. A total of 4,231 HCC patients from eight RCTs were included for analysis, with 1,607 patients aged ≥ 65 years and 2,624 patients aged < 65 years. The pooled results demonstrated that the use of MTAs in patients < 65 years significantly improved PFS (HR 0.69, 95% CI: 0.51–0.95, p = 0.023) and OS (HR 0.79, 95% CI: 0.69–0.89, p < 0.001) when compared to controls. For HCC patients aged ≥ 65 years, the use of MTAs significantly improved PFS (HR 0.66, 95% CI: 0.53–0.84, p = 0.001) but not for OS (HR 0.94, 95% CI: 0.81 –1.09, p = 0.41). No publication bias was detected by Begg’s and Egger’s tests for OS. Therefore, the treatment effect of MTAs on OS might be different in younger and older HCC patients undergoing first-line or second-line treatment, but not for PFS benefit.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.